Analysis of the sugar specificity and molecular location of the beta-glucan-binding lectin site of complement receptor type 3 (CD11b/CD18).
Zymosan, the cell wall from Saccharomyces cerevisiae, was reported to be a macrophage activator through its beta-glucan over 30 yr ago. Nevertheless, the identity of the beta-glucan receptor has been controversial. This study showed that the alpha M beta 2-integrin, CR3 (Mac-1, CD11b/CD18) served as the beta-glucan receptor through one or more lectin sites located outside of the CD11b I-domain that contains the binding sites for iC3b, ICAM-1, and fibrinogen. Sugar specificity, analyzed with FITC-labeled soluble polysaccharides and flow cytometry, showed CR3-specific staining with several pure beta-glucans but not with alpha-mannan. However, a 10-kDa soluble zymosan polysaccharide (SZP) with high affinity (6.7 x 10(-8) M) for CR3 consisted largely of mannose and approximately 5% glucose. Binding of either SZP-FITC or beta-glucan-FITC to CR3 was blocked not only by pure beta-glucans from yeast, mushroom, seaweed, or barley, but also by N-acetyl-D-glucosamine (NADG), alpha- or beta-methylmannoside, and alpha- or beta-methyl-glucoside. SZP-FITC and beta-glucan-FITC stained all leukocyte types similarly to anti-CR3-FITC, and polysaccharide-FITC staining was inhibited > or = 95% by unlabeled anti-CR3. SZP-FITC staining of cells expressing recombinant chimeras between CR3 and CR4 (p150,95, CD11c/CD18) suggested that both the divalent cation-binding region of CD11b and the region C-terminal to it may regulate binding of polysaccharides to CR3. Unlabeled SZP or beta-glucan also blocked CR3 staining by 11 mAb to C-terminal domain epitopes of CD11b but had no effect on staining by mAb directed to the I-domain. In conclusion, CR3 serves as the leukocyte beta-glucan receptor through a cation-independent lectin site located C-terminal to the I-domain of CD11b. Its sugar specificity is broader than originally appreciated, allowing it to react with certain polysaccharides containing mannose or NADG, as well as glucose.
Thornton
B P
BP
Department of Pathology, University of Louisville, KY 40292, USA.
Vĕtvicka
V
V
Pitman
M
M
Goldman
R C
RC
Ross
G D
GD
D000818:Animals; D000911:Antibodies, Monoclonal / Q000737:chemistry / Q000494:pharmacology; D001666:Binding Sites, Antibody; D001667:Binding, Competitive / Q000276:immunology; D018845:CD11 Antigens / Q000032:analysis; D018821:CD18 Antigens / Q000032:analysis; D016466:CHO Cells; D006224:Cricetinae; D000939:Epitopes / Q000737:chemistry; D019084:Fluorescent Antibody Technique, Indirect; D006801:Humans; D007962:Leukocytes / Q000737:chemistry; D016177:Macrophage-1 Antigen / Q000737:chemistry* / Q000276:immunology; D010449:Peptide Mapping; D011134:Polysaccharides / Q000737:chemistry* / Q000276:immunology; D011951:Receptors, Complement / Q000737:chemistry; D011971:Receptors, Immunologic / Q000737:chemistry*; D011975:Receptors, Mitogen / Q000737:chemistry*; D011994:Recombinant Proteins / Q000737:chemistry; D015054:Zymosan / Q000737:chemistry / Q000302:isolation & purification
D000911:Antibodies, Monoclonal; D018845:CD11 Antigens; D018821:CD18 Antigens; D000939:Epitopes; D016177:Macrophage-1 Antigen; D011134:Polysaccharides; D011951:Receptors, Complement; D011971:Receptors, Immunologic; D011975:Receptors, Mitogen; D011994:Recombinant Proteins; C045268:beta-glucan receptor; C048084:zymosan receptor; D015054:Zymosan